Charles Schwab Investment Management Inc. Purchases 14,558 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Charles Schwab Investment Management Inc. increased its position in shares of Bausch Health Companies Inc. (NYSE:BHC) by 1.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,284,036 shares of the company’s stock after acquiring an additional 14,558 shares during the period. Charles Schwab Investment Management Inc. owned about 0.36% of Bausch Health Companies worth $10,375,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BHC. Goldentree Asset Management LP grew its position in Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock worth $239,552,000 after acquiring an additional 6,958,717 shares during the last quarter. Bank of Montreal Can grew its position in shares of Bausch Health Companies by 234.0% in the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after buying an additional 2,685,675 shares during the last quarter. Maple Rock Capital Partners Inc. bought a new stake in shares of Bausch Health Companies in the 3rd quarter valued at about $16,850,000. SG Americas Securities LLC grew its position in shares of Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after buying an additional 1,263,706 shares during the last quarter. Finally, Readystate Asset Management LP grew its position in shares of Bausch Health Companies by 38.1% in the 3rd quarter. Readystate Asset Management LP now owns 470,761 shares of the company’s stock valued at $3,841,000 after buying an additional 130,000 shares during the last quarter. Institutional investors own 78.65% of the company’s stock.

Analyst Upgrades and Downgrades

BHC has been the topic of a number of analyst reports. Royal Bank of Canada reduced their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Thursday, January 30th. Jefferies Financial Group reiterated a “hold” rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $7.42.

Bausch Health Companies Price Performance

Shares of NYSE:BHC opened at $7.17 on Friday. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -59.70, a P/E/G ratio of 0.37 and a beta of 0.59. The business’s 50-day moving average is $7.14 and its 200-day moving average is $7.69. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. Analysts anticipate that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.